Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 switch-over dose-escalation study of HPN-100 versus sodium phenylbutyrate in urea cycle disorders
2008-003865-23Phase 2Terminated
- Sponsor
- Hyperion Therapeutics, Inc.
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycerol phenylbutyrate and sodium phenylbutyrate in urea cycle disorder (UCD), sponsored by Hyperion Therapeutics, Inc. Primary endpoint: Safety and tolerability of escalating doses of HPN-100 compared with constant-dose sodium phenylbutyrate. Started Jul 2008; status: terminated.
02
Drugs
glycerol phenylbutyratesodium phenylbutyrate
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on 2008-003865-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003865-23.